| 摘要: |
| 目的 评价硝苯地平缓释片Ⅱ(伲福达)治疗原发性高血压的疗效。方法选取2016年3月~2017年3月期间本院收治的140例原发性高血压患者作为研究对象,随机分为对照组(68例)和观察组(72例)。对照组采用美托洛尔治疗,观察组采用硝苯地平缓释片Ⅱ治疗,治疗期间监测两组患者血压和心率变化,并比较两组临床疗效和用药安全性。结果治疗后,观察组SBP/DBP指标水平(128.56±10.23/84.24±6.02 mmHg)均显著低于对照组(143.58±11.71/90.47±5.24 mmHg),组间有差异P<0.05。观察组总有效率(94.44%,68/72)显著高于对照组(76.47%,52/68),组间有差异(P<0.05)。观察组不良反应发生率(13.89%,10/72)略高于对照组(11.76%,8/68),但无显著差异(P<0.05)。结论原发性高血压患者应用伲福达治疗效果可靠,可有效提升降压效果,改善患者心率,临床应用安全高效。 |
| 关键词: 硝苯地平缓释片Ⅱ 原发性高血压 临床疗效 优越性 |
| DOI:10.13506/j.cnki.jpr.2017.12.015 |
| 基金项目: |
|
|
|
| The efficacy and superiority of the treatment of primary hypertension with Nifedipine Substained-release Tablets Ⅱ |
| FAN Zhenxing |
| (Jiaozuo Hospital of Traditional Chinese Medicine,Jiaozuo 454100,China) |
| Abstract: |
| ObjectiveTo evaluate the efficacy and superiority of the treatment of primary hypertension. Methods In this study,140 patients with primary hypertension, who were admitted to the hospital in March, 2016, were randomly divided into control group (68 cases) and observation group (72 cases).The control group was treated with metoprolol, and the observation group was treated with the treatment of Nifuda, which monitored the blood pressure and heart rate changes in the two groups during the treatment, and compared the clinical efficacy and drug safety of the two groups.Results After treatment,the SBP/DBP index level of the observation group (128.56 plus or minus 10.23/84.24, plus or minus 6.02 mmHg) was significantly lower than that in the control group (143.58+11.71/90.47 or 0.47 mmHg), and the difference between groups was significant(P<0.05).The incidence of adverse reactions (13.89%,10/72) was slightly higher than the control group (11.76%,8/68),but no significant difference wassignificant(P<0.05).ConclusionThetreatmentof patients with primary hypertension was reliable,which can effectively improve the effect of blood pressure,improve the heart rate of patients,and be safe and effective in clinical application. |
| Key words: Nifuda Primary hypertension Clinical efficacy Superiority |